Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to -$50.2 million.

  • Denali Therapeutics' Net Cash Flow fell 41487.12% to -$50.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 10323.83%. This contributed to the annual value of $47.9 million for FY2024, which is 15266.61% up from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Net Cash Flow is -$50.2 million, which was down 41487.12% from $84.3 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Net Cash Flow ranged from a high of $99.4 million in Q4 2022 and a low of -$188.5 million during Q1 2022
  • For the 5-year period, Denali Therapeutics' Net Cash Flow averaged around -$21.8 million, with its median value being -$20.9 million (2023).
  • Per our database at Business Quant, Denali Therapeutics' Net Cash Flow soared by 50336.76% in 2024 and then plummeted by 41487.12% in 2025.
  • Over the past 5 years, Denali Therapeutics' Net Cash Flow (Quarter) stood at -$101.1 million in 2021, then soared by 198.37% to $99.4 million in 2022, then tumbled by 121.03% to -$20.9 million in 2023, then surged by 503.37% to $84.3 million in 2024, then tumbled by 159.58% to -$50.2 million in 2025.
  • Its Net Cash Flow stands at -$50.2 million for Q3 2025, versus $84.3 million for Q2 2025 and -$116.5 million for Q1 2025.